c-Met-IN-23 

c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent^[1].

c-Met-IN-23 (72 h) inhibits HGF-induced cell proliferation, with IC₅₀s of 12.4, 3.06, 19.30, 16.85 µM for HT29, HepG2, MCF7, MDA-MB-231 cells respectively^[1].
c-Met-IN-23 (0.3-150 µM, 30 min) blocks P-gp and MRP1/2 pumps in both HepG2 and BxPC3 cells^[1].
c-Met-IN-23 (3 µM, 24 h) increases the expression of P-gp in HepG2 and BxPC3 cells, as well as MRP1 and MRP2 in BxPC3 cells, and inhibits the P-gp-mediated efflux in HepG2 cell^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

319.32

C₁₆H₁₃N₇O

OC1=CC=C(C2=NN3C(N=C2)=NN=C3NCC4=CC=NC=C4)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Khatir ZZ, et al. 4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator. Arch Pharm (Weinheim). 2024 Mar 5:e2300704.  [Content Brief]